Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Assets: 2019-2024

Historic Assets for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $919.3 million.

  • BridgeBio Pharma's Assets rose 50.12% to $998.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $998.2 million, marking a year-over-year increase of 50.12%. This contributed to the annual value of $919.3 million for FY2024, which is 68.26% up from last year.
  • BridgeBio Pharma's Assets amounted to $919.3 million in FY2024, which was up 68.26% from $546.4 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Assets ranged from a high of $1.0 billion in FY2021 and a low of $546.4 million during FY2023.
  • Over the past 3 years, BridgeBio Pharma's median Assets value was $623.0 million (recorded in 2022), while the average stood at $696.3 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Assets tumbled by 38.48% in 2022, and later spiked by 68.26% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Assets (Yearly) stood at $703.6 million in 2020, then skyrocketed by 43.95% to $1.0 billion in 2021, then tumbled by 38.48% to $623.0 million in 2022, then declined by 12.30% to $546.4 million in 2023, then skyrocketed by 68.26% to $919.3 million in 2024.